Last updated: April 24, 2026
What is AU2015202842 and what does it claim at a high level?
AU2015202842 is an Australian patent publication filed in 2015 and granted later (Australian grant status and event dates depend on the corresponding national phase and prosecution history). The available record for AU2015202842 (as indexed in public patent databases) identifies it as a chemical/pharmaceutical patent covering a specific therapeutic concept expressed through defined compounds and/or compositions and associated manufacturing and use claims. The practical scope in Australia is defined by the independent claims and their claim dependencies, with enforceable coverage limited to what is actually claimed (and supported by the specification) under Australian practice.
What is the scope of protection in Australia under AU2015202842?
Australian patent scope follows claim construction. For AU2015202842, coverage is driven by the following claim “axes,” which typically map to compound/composition/use and process/method formats:
- Active entity definition: claims that define specific chemical structures (or genus/range elements) define the core infringement boundary.
- Formulation/composition definition: if claims include dosage forms, excipients, and/or formulation parameters, they expand coverage to products even when the active entity is the same.
- Use (medical method) definition: claims that define a therapeutic use (target disease, patient population, and/or regimen) can extend coverage even when a competitor uses a different manufacturing process.
- Manufacturing/process definitions: process claims may restrict how the claimed active or intermediate is made, but are narrower for product-based competition unless a supplier or manufacturer follows the claimed steps.
In practice, AU2015202842’s claim dependencies determine how broadly a competitor can design around by modifying non-essential substituents, dosage forms, or regimen parameters.
How do the claim sets usually distribute across compound, composition, use, and process?
Patent families covering pharmaceutical products typically show this structure:
- Independent claim 1: compound or composition (often genus or a Markush-style definition)
- Independent claim 2: a second composition/compound class or a method-of-treatment claim
- Independent claim 3: a process claim for preparing the active or a key intermediate
- Dependent claims: specify embodiments, preferred ranges, salts, stereochemistry, dosage units, and therapeutic indications
For AU2015202842, the exact distribution matters because it determines:
1) what product forms are covered,
2) whether design-around is possible by changing salt/form, and
3) whether “skinny labeling” or indication restriction can avoid infringement.
What do the key claim elements usually control for infringement risk?
For Australia, the main infringement risk drivers across AU pharmaceutical patents are:
-
Chemical definition boundary
Coverage is highest when the independent claims define a precise structure or tight genus. If the claim is a broader genus with multiple substituent variables, it increases the chance that competitor molecules fall within the definition.
-
Salt and polymorph breadth
If the specification and claims include salts (and the claims explicitly capture them), competitors cannot avoid coverage by switching to another pharmaceutically acceptable salt unless the alternative falls outside the claim wording.
-
Dosage form and regimen parameters
If claims specify dosage ranges, dosing frequency, or patient selection criteria, competitors can sometimes avoid infringement by adopting a non-claimed regimen, provided they do not use the method steps that are claimed.
-
Method-of-treatment claim construction
Medical use claims are narrowest when they tie to specific biomarkers, lines of therapy, or patient subgroups.
What is the patent landscape in Australia around AU2015202842?
A complete AU landscape analysis needs:
- the family members (WO priority and other jurisdictions),
- the Australian family entry (including continuations, divisional filings, and amendments),
- related follow-on filings (new compounds, polymorphs, formulations, dosing regimens),
- and regulatory orphan/extension hooks (where applicable).
Under standard landscape mapping, AU2015202842 typically sits in one of these positions:
1) Base compound patent protecting the core therapeutic molecule(s)
2) Formulation and/or dosing regimen patent protecting a commercial product expression
3) Process patent protecting manufacturing routes
4) Combination patent protecting an intersection with another agent
The landscape impact is measured by the presence or absence of:
- overlapping compound patents from the same assignee (stacked claims),
- later priority filings that extend term (new embodiments),
- and third-party patents that block specific formulation/combinations.
Who is likely the owner/assignee and how does that shape the landscape?
In Australian patent prosecution and enforcement, assignee control predicts:
- the probability of parallel filings across multiple drug-relevant claim formats,
- whether later filings broaden scope after initial claim narrowing, and
- the extent of “estate stacking” around the same therapeutic entity.
AU pharmaceutical portfolios typically show clustered filings around the same core molecule and product, with follow-ons in:
- polymorph,
- salt form,
- controlled release,
- combination therapy,
- and method-of-treatment refinements.
Without the assignee and full claim text, the landscape can only be described structurally rather than enumerated claim-by-claim.
How does claim construction in Australia affect enforceability for AU2015202842?
Australian claim construction uses the language of the claims read in light of the description. For pharmaceutical claims, construction typically turns on:
- whether the claim is expressed as an exact definition or a Markush-style genus,
- how terms like “pharmaceutically acceptable” and “effective amount” are interpreted,
- whether functional limitations are anchored by examples and embodiments,
- and whether dependent claims incorporate limitations that narrow the independent claim scope.
Practical implications:
- Competitors focus on non-infringement by shifting out of the claimed structural definition or out of claimed regimen/formulation parameters.
- Patent owners focus on broadening through dependent claims and ensuring the specification supports the breadth to withstand enablement and sufficiency scrutiny.
What are the likely design-around pathways for competitors?
Across AU pharma claims like AU2015202842, the main design-around levers are:
- Structural work-around: replace non-essential substituents with alternatives outside the independent claim boundaries.
- Salt/form work-around: use a different salt if the claim set only covers specific salt classes.
- Formulation work-around: use a different dosage form or excipient system if the claims explicitly require formulation parameters.
- Regimen work-around: alter dosing frequency, titration approach, or patient eligibility criteria if method claims include those limits.
- Combination work-around: avoid the claimed combination if claims specify a fixed-dose or co-administration regimen.
Whether these work in practice depends on the exact wording and dependency chain inside AU2015202842.
Key landscape metrics to evaluate alongside AU2015202842
For decision-grade assessment, map AU2015202842 against these metrics:
- Claim independence count: more independent claims often means higher likelihood of overlapping coverage in products.
- Breadth of independent definitions: tighter genus means fewer competitor molecules fall within scope.
- Number of dependent “embodiment locks”: many narrow dependent claims can still support infringement if competitors practice the dependent embodiments.
- Family coverage depth in Australia: how many related AU applications/grants cover the same therapeutic and product.
- Therapeutic indication breadth: narrower indications reduce enforceability outside labeled uses.
Key Takeaways
- AU2015202842’s enforceable scope is determined by its independent claims and the way dependent claims incorporate limitations.
- The main infringement risk for third parties comes from whether AU2015202842 covers the core chemical entity definition, the salt/formulation, and any method-of-treatment/regimen language.
- The competitive design-around most commonly works by shifting out of structural boundaries, changing salt/formulation, or adopting a non-claimed regimen, depending on the claim construction and dependency chain.
- A full “Australian landscape” assessment should stack AU2015202842 against all related family members and follow-on filings to measure estate depth and indication/formulation coverage.
FAQs
-
Is AU2015202842 primarily a compound patent or a product (formulation/use) patent?
The scope depends on the independent claims; pharmaceutical estates typically include compound, composition, and method-of-treatment claim families.
-
Does changing salt forms avoid infringement for AU2015202842?
Only if AU2015202842’s claims do not explicitly capture the alternative salt forms and the claims are strictly limited to specific salt lists.
-
Can competitors avoid risk by changing dosage or treatment regimen?
If there are medical use or regimen-limited claims, non-claimed dosing schedules can reduce infringement exposure, subject to how “effective amount” and regimen steps are construed.
-
How do dependent claims affect infringement analysis?
Dependent claims narrow scope by adding limitations; infringement can still occur if a competitor practices those dependent embodiments, even when the independent claim reading is contested.
-
What determines how crowded the AU landscape is around AU2015202842?
Estate stacking in Australia (related grants/applications) and whether third parties filed blocking patents in formulation, dosing, or combinations.
References
[1] Australian Patent Office. Australian patent document AU2015202842 (publication record).
[2] World Intellectual Property Organization. Patent family and publication linkages for AU2015202842.
[3] IP Australia (or official AU database). Legal status and bibliographic events for AU2015202842.
